23109841|t|Erythropoietin: new directions for the nervous system.
23109841|a|New treatment strategies with erythropoietin (EPO) offer exciting opportunities to prevent the onset and progression of neurodegenerative disorders that currently lack effective therapy and can progress to devastating disability in patients. EPO and its receptor are present in multiple systems of the body and can impact disease progression in the nervous, vascular, and immune systems that ultimately affect disorders such as Alzheimer's disease, Parkinson's disease, retinal injury, stroke, and demyelinating disease. EPO relies upon wingless signaling with Wnt1 and an intimate relationship with the pathways of phosphoinositide 3-kinase (PI 3-K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR). Modulation of these pathways by EPO can govern the apoptotic cascade to control beta-catenin, glycogen synthase kinase-3beta, mitochondrial permeability, cytochrome c release, and caspase activation. Yet, EPO and each of these downstream pathways require precise biological modulation to avert complications associated with the vascular system, tumorigenesis, and progression of nervous system disorders. Further understanding of the intimate and complex relationship of EPO and the signaling pathways of Wnt, PI 3-K, Akt, and mTOR are critical for the effective clinical translation of these cell pathways into robust treatments for neurodegenerative disorders.
23109841	0	14	Erythropoietin	Gene	2056
23109841	85	99	erythropoietin	Gene	2056
23109841	101	104	EPO	Gene	2056
23109841	175	202	neurodegenerative disorders	Disease	MESH:D019636
23109841	287	295	patients	Species	9606
23109841	297	300	EPO	Gene	2056
23109841	483	502	Alzheimer's disease	Disease	MESH:D000544
23109841	504	523	Parkinson's disease	Disease	MESH:D010300
23109841	525	539	retinal injury	Disease	MESH:D012173
23109841	541	547	stroke	Disease	MESH:D020521
23109841	553	574	demyelinating disease	Disease	MESH:D003711
23109841	576	579	EPO	Gene	2056
23109841	616	620	Wnt1	Gene	7471
23109841	671	696	phosphoinositide 3-kinase	Gene	5293
23109841	707	723	protein kinase B	Gene	2185
23109841	725	728	Akt	Gene	207
23109841	735	764	mammalian target of rapamycin	Gene	2475
23109841	766	770	mTOR	Gene	2475
23109841	805	808	EPO	Gene	2056
23109841	853	865	beta-catenin	Gene	1499
23109841	867	897	glycogen synthase kinase-3beta	Gene	2932
23109841	927	939	cytochrome c	Gene	54205
23109841	978	981	EPO	Gene	2056
23109841	1152	1176	nervous system disorders	Disease	MESH:D009422
23109841	1244	1247	EPO	Gene	2056
23109841	1291	1294	Akt	Gene	207
23109841	1300	1304	mTOR	Gene	2475
23109841	1407	1434	neurodegenerative disorders	Disease	MESH:D019636
23109841	Association	1499	2056
23109841	Association	2056	7471
23109841	Association	MESH:D019636	207
23109841	Association	MESH:D010300	2056
23109841	Association	2056	54205
23109841	Association	2056	5293
23109841	Association	MESH:D000544	2056
23109841	Association	2056	2932
23109841	Association	MESH:D012173	2056
23109841	Association	2056	207
23109841	Association	2056	2185
23109841	Association	2056	2475
23109841	Association	MESH:D020521	2056
23109841	Association	MESH:D009422	2056
23109841	Association	MESH:D019636	2475
23109841	Negative_Correlation	MESH:D019636	2056
23109841	Association	MESH:D003711	2056

